NEW YORK, NY / ACCESSWIRE / January 23, 2018 / U.S. markets closed in the green on Monday after the Senate reached a deal to end the government shutdown. The Dow Jones Industrial Average gained 0.55 percent to close at 26,214.60, while the S&P 500 Index rose 0.81 percent to close at 2,832.97. The Nasdaq Composite Index jumped 0.98 percent to close at 7,408.03. On Monday, Senate members agreed to keep the government open through February 8th.

"Investors have learned from history that shutdowns don't impact markets, so it's not surprising to see stock prices higher," said Kristina Hooper, chief global market strategist at Invesco, according to MarketWatch.

"The biggest geopolitical risk to markets in the long term is trade-protectionist policies. In the short-term, the wrangling over the debt ceiling is likely to spook investors a lot more than shutdown does because the impact on markets is direct," Hooper said.

RDI Initiates Coverage on:

Spectrum Pharmaceuticals, Inc.
https://rdinvesting.com/news/?ticker=SPPI

ZIOPHARM Oncology Inc.
https://rdinvesting.com/news/?ticker=ZIOP

Spectrum Pharmaceuticals stock jumped 9.93% on Monday, to close the day at $20.92. The stock recorded a trading volume of 1,675,953 shares, which was above its three months average volume of 1,186,980 shares. In the last year, Spectrum Pharmaceuticals shares have traded in a range of 4.31 - 21.95. The share price has gained 385.38% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $18.67 is greater than its 200-day moving average of $14.17. Shares of Spectrum Pharmaceuticals have gained roughly 15.9 percent in the past month and are up 10.4 percent year-to-date.

Access RDI's Spectrum Pharmaceuticals, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=SPPI

On Monday, shares of ZIOPHARM Oncology recorded a trading volume of 8,415,345 shares, which was above the three months average volume of 1,863,026 shares. The stock ended the day 20.09% higher at 5.14. The share price has gained 36.34% from its 52 week low with a 52 week trading range of 3.77 - 7.88. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $4.26 is below its 200-day moving average of $5.24. Shares of ZIOPHARM Oncology have gained roughly 26.91 percent in the past month and are up 24.15 percent year-to-date.

Access RDI's ZIOPHARM Oncology Inc. Research Report at:
https://rdinvesting.com/news/?ticker=ZIOP

Our Actionable Research on Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) and ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com